Home » Blog » NCCN Launches Value Tool and American Cancer Society Recommends Fewer Mammograms

NCCN Launches Value Tool and American Cancer Society Recommends Fewer Mammograms

IP Blog | Dave Melin | October 25, 2015

BioBlog Weekly oncologyThis week in healthcare: as the quest to measure value in cancer treatment continues, NCCN has released a value-evaluation tool, Evidence Blocks, for multiple myeloma and chronic myelogenous leukemia with more to follow in the coming year. And, in an update to their previous recommendation, the American Cancer Society has announced that they suggest women begin receiving mammograms later in life and less often.

U.S. Oncology Group Rates Blood Cancer Regimens, Including Cost

NCCN has released “evidence blocks” to help doctors and patients assess treatments for multiple myeloma and chronic myelogenous leukemia, which they say are “the first in a series that by the end of next year will encompass all oncology therapies, other than surgery or radiation.”

Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update from the American Cancer Society

In an update to their previous recommendation from 2003, the American Cancer Society “recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years.”

American Cancer Society, in a Shift, Recommends Fewer Mammograms

This write-up from the New York Times notes that the American Cancer Society’s new recommendation is for mammograms to “begin… later” and “less frequently” than their previous recommendation.

Is Google a Competitor or a Partner to Big Pharma? Roche’s CEO Doesn’t Know, Yet

As Google continues to develop its health offerings, some in the health industry ponder the question recently put to Roche CEO Severin Schwan: “Google: Competitor or partner in the future?” And many, like Schwan, are unsure how to answer.

New Tools from NCCN and ASCO Address Value

This article gives a thorough overview of value-measurement tools for cancer treatment provided by NCCN (Evidence Blocks) and ASCO (Value Framework).

Hot Startup Theranos Dials Back Lab Tests at FDA’s Behest

As rising star Silicon Valley startup Theranos seeks to “revolutionize the blood testing industry,” it has slowed its flight somewhat — at the request of the FDA.

What the ACS Guidelines Got Wrong about Breast Cancer Screening

In this Forbes article, Elaine Schattner argues that the American Cancer Society’s shift to recommending less frequent mammograms is “a huge mistake, one which will cost lives, and add costs – along with plenty of treatment toxicity – by delaying diagnosis.”

With New Startup, Caperna, Moderna Gets in on Cancer Vaccine Buzz

Moderna Therapeutics of Boston, MA recently announced the launch of a fourth subsidiary startup, Caperna, which “will focus solely on mRNA vaccines for cancer.”

Oncology Experts Share Essential Actions to Achieve a Positive Impact on Patient Care in the Integrated Health Environment

At its annual meeting this weekend, ACCC will release a white paper to address “five essential actions for achieving a positive impact on patient care within the next decade.”

Biden’s Bid for a Legacy: A Moon Shot for Cancer

In his announcement that he would not seek the presidency in 2016, Vice President Joe Biden suggested that instead he would pursue a cure for the disease that recently took the life of his son, Beau: “I believe we need a moon shot in this country to cure cancer. It’s personal. But I know we can do this. … I’m going to spend the next 15 months in this office pushing as hard as I can to accomplish this, because I know there are Democrats and Republicans on the Hill who share our passion—our passion to silence this deadly disease.”

A Surprising Factor that May Increase Voter Turnout: A Cancer Diagnosis

A recent study to “examine the link between voter turnout in the 2008 election and five widespread chronic illnesses: cancer, heart disease, diabetes, asthma, and arthritis” found that those with cancer were more likely to vote than those with the other four diseases studied.

Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.

Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *